Bank of New York Mellon’s Strongbridge Biopharma plc. SBBP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-51,948
| Closed | -$106K | – | 4724 |
|
|
2021
Q3 | $106K | Hold |
51,948
| – | – | ﹤0.01% | 4325 |
|
|
2021
Q2 | $154K | Sell |
51,948
-113,597
| -69% | -$300K | ﹤0.01% | 4147 |
|
|
2021
Q1 | $457K | Buy |
165,545
+9,663
| +6% | +$29.2K | ﹤0.01% | 3739 |
|
|
2020
Q4 | $379K | Buy |
155,882
+70,297
| +82% | +$169K | ﹤0.01% | 3742 |
|
|
2020
Q3 | $180K | Sell |
85,585
-938
| -1% | -$3.16K | ﹤0.01% | 3870 |
|
|
2020
Q2 | $327K | Sell |
86,523
-12,628
| -13% | -$37.8K | ﹤0.01% | 3667 |
|
|
2020
Q1 | $187K | Buy |
99,151
+1,747
| +2% | +$4.54K | ﹤0.01% | 3757 |
|
|
2019
Q4 | $204K | Hold |
97,404
| – | – | ﹤0.01% | 3913 |
|
|
2019
Q3 | $233K | Sell |
97,404
-3,268
| -3% | -$8.78K | ﹤0.01% | 3867 |
|
|
2019
Q2 | $315K | Buy |
+100,672
| New | +$370K | ﹤0.01% | 3794 |
|
|
2018
Q2 | – | Sell |
-67,671
| Closed | -$599K | – | 4342 |
|
|
2018
Q1 | $599K | Buy |
67,671
+19,240
| +40% | +$144K | ﹤0.01% | 3495 |
|
|
2017
Q4 | $351K | Buy |
48,431
+2,398
| +5% | +$15K | ﹤0.01% | 3753 |
|
|
2017
Q3 | $318K | Sell |
46,033
-138
| -0.3% | -$952 | ﹤0.01% | 3743 |
|
|
2017
Q2 | $331K | Buy |
+46,171
| New | +$213K | ﹤0.01% | 3780 |
|
Bank of New York Mellon's SBBP Position: Q4 2021 in Review
Bank of New York Mellon sold out of Strongbridge Biopharma plc. (SBBP) in Q4 2021, closing a stake of 51,948 shares — an estimated $106K sold.
Bank of New York Mellon first reported a position in SBBP in Q2 2017 and held it in 14 quarters. The position peaked at $599K in Q1 2018. 0 funds tracked by Wall St. Rank hold SBBP as of Q4 2021.
- Bank of New York Mellon reported no remaining Strongbridge Biopharma plc. position as of Q4 2021 after selling out during the quarter.
- Bank of New York Mellon sold 51,948 Strongbridge Biopharma plc. shares in Q4 2021, an estimated $106K.
- Bank of New York Mellon first reported a position in Strongbridge Biopharma plc. in Q2 2017 and held it in 14 quarters.
- Bank of New York Mellon's Strongbridge Biopharma plc. position peaked at $599K in Q1 2018.
- 0 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q4 2021.
Based on Bank of New York Mellon's 13F filing for Q4 2021, filed 11 Feb 2022.